Adaptive Biotechnologies (ADPT) president sells 57K shares, exercises options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported a mix of option exercises and share sales. Over April 22–24, 2026, she exercised stock options covering 44,166 shares of Common Stock at an exercise price of $8.46 per share and sold 57,180 shares in open-market transactions at weighted average prices around $14 per share, as detailed in price ranges in the footnotes. After these transactions, she directly holds 382,132 shares of Common Stock and 60,438 stock options. The filing notes that all transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025.
Positive
- None.
Negative
- None.
Insights
Rubinstein executes 10b5-1 exercise-and-sell plan, trimming but retaining a large stake.
Adaptive Biotechnologies’ President and COO Julie Rubinstein exercised options for 44,166 shares of Common Stock at an exercise price of $8.46 and sold 57,180 shares in open-market trades around $14. These are classic exercise-and-sell transactions.
Following the trades, she directly holds 382,132 Common shares plus 60,438 stock options, so the sales represent a modest portion of her overall equity exposure. The filing specifies that all transactions were carried out under a Rule 10b5-1 trading plan adopted on November 18, 2025, indicating the timing was pre-planned rather than discretionary.
The net effect is a reduction of 57,180 shares while maintaining substantial ownership and remaining option incentives. For observers of insider activity, this pattern generally looks like routine liquidity management tied to compensation rather than a wholesale change in alignment.
Insider Trade Summary 10b5-1
Net Seller: 57,180 shares ($798,423)
Net Sell
9 txns
Insider
RUBINSTEIN JULIE
Role
President and COO
Sold
57,180 shs ($798K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | -- |
| Exercise | Common Stock | 14,722 | $8.46 | $125K |
| Sale | Common Stock | 19,060 | $14.02 | $267K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | -- |
| Exercise | Common Stock | 14,722 | $8.46 | $125K |
| Sale | Common Stock | 19,060 | $13.74 | $262K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | -- |
| Exercise | Common Stock | 14,722 | $8.46 | $125K |
| Sale | Common Stock | 19,060 | $14.13 | $269K |
Holdings After Transaction:
Stock Option (right to buy) — 60,438 shares (Direct, null);
Common Stock — 401,192 shares (Direct, null)
Footnotes (1)
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.97 to $14.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.52 to $14.14, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.79 to $14.16, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Key Figures
Shares sold: 57,180 shares
Options exercised: 44,166 shares
Exercise price: $8.46 per share
+5 more
8 metrics
Shares sold
57,180 shares
Open-market sales of Common Stock over April 22–24, 2026
Options exercised
44,166 shares
Stock options exercised into Common Stock
Exercise price
$8.46 per share
Conversion or exercise price of stock options
Sale prices
$13.52–$14.44 per share
Price ranges for weighted average sales in footnotes
Common shares after trades
382,132 shares
Direct Common Stock holdings following transactions
Options remaining
60,438 options
Stock Option (right to buy) position after exercises
10b5-1 plan adoption date
November 18, 2025
Date pre-arranged trading plan was adopted
Transactions span
3 days
Trades on April 22, 23, and 24, 2026
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (right to buy), open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
FAQ
What did Adaptive Biotechnologies (ADPT) executive Julie Rubinstein report in this Form 4?
Julie Rubinstein reported exercising stock options and selling common shares. She exercised 44,166 options at an exercise price of $8.46 and sold 57,180 shares in open-market trades around $14 per share, all under a pre-arranged Rule 10b5-1 trading plan.
How many Adaptive Biotechnologies (ADPT) options did Julie Rubinstein exercise in this filing?
Rubinstein exercised stock options covering 44,166 shares of Adaptive Biotechnologies common stock. These options had a conversion or exercise price of $8.46 per share, reflecting compensation-related equity being converted into common shares and then partially sold in the market.
What are Julie Rubinstein’s Adaptive Biotechnologies (ADPT) holdings after these transactions?
After the reported trades, Rubinstein directly holds 382,132 shares of Adaptive Biotechnologies common stock. She also has 60,438 stock options outstanding, providing additional potential future equity exposure beyond her current common share ownership position.
Were Julie Rubinstein’s Adaptive Biotechnologies (ADPT) trades made under a Rule 10b5-1 plan?
Yes. A footnote states that all transactions in this Form 4 were effected under a Rule 10b5-1 trading plan adopted on November 18, 2025. Such plans pre-schedule trades, helping separate routine liquidity events from discretionary timing decisions.
Over what dates did Adaptive Biotechnologies (ADPT) executive Julie Rubinstein transact these shares?
The reported transactions occurred over three consecutive days: April 22, 23, and 24, 2026. Each day involved exercising options for 14,722 shares at $8.46 per share and selling 19,060 common shares at weighted average prices in the low-to-mid $14 range.